Inactief instrument

Andere talen Pulmatrix Inc Nasdaq

Aandelen

US74584P1030

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K	15/05
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update	13/05
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	10/05
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	13/03
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives	09/01
Pulmatrix Explores Strategic Alternatives	08/01
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	08/01
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	08/01
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update	10/11
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	09/11
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine	20-09-23
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	24-08-23
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update	11-08-23
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10-08-23
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M	10-08-23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	12-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pulmatrix Inc Nasdaq

Aandelen

US74584P1030

Andere talen

Filters